CLDN 18.2

CLDN18.2 resources

View additional resources to learn more about how to consistently test, interpret, and report CLDN18.2 in G/GEJ cancer.

Books on bookshelves
Books on bookshelves

Resources

Publications and assessments

Fassan 2024 publication

View the publication, “Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach.”

Shitara 2024 publication

View the publication, “Global Prevalence of Claudin 18 Isoform 2 in Tumors of Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.”

VENTANA® CLDN18 (43-14A) RxDx Assay
performance publication 2025

View the publication, Analytical and Clinical Performance of the VENTANA® CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples in 2 Phase 3 clinical trials.

Global concordance study publication

View the global concordance study publication, which assesses the performance and reproducibility of three CLDN18.2 antibodies: 43-14A, EPR19202, and ZR451 in gastric cancer.

NordiQC External Quality Assessment

Access the 2025 assessment and more information about NordiQC.


NordiQC External Quality Assessment

Access the 2025 assessment and more information about NordiQC.


Tools and guides

eLearning center

Access a self-guided CLDN18.2 educational program.

IHC assay guide

Explore our expert-recommended IHC Implementation Guide to help you set up a new biomarker assay in your lab.

CLDN18.2, claudin 18 isoform 2; G/GEJ, gastric/gastroesophageal junction.